As a novel AD therapy that is comparable to immunotherapies, we have developed the photo-oxygenation technology, which can attach oxygen atoms artificially to amyloid fibrils, such as those of Aβ and tau, because oxidated Aβ showed the low aggregation potency. This evidence concerns the gene MAPT and Alzheimer disease.